Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Vandana Singh

Why Trevi Therapeutics Shares Trading Higher Today?

  • Trevi Therapeutics Inc (NASDAQ:TRVI) has announced positive results from its Phase 2b/3 PRISM trial of Haduvio in treating prurigo nodularis, a chronic disease characterized by severe pruritus and the presence of nodules, lesions, and excoriations. 
  • In the trial, results comparing subjects randomized to Haduvio monotherapy (n=168) or placebo (n=176) showed that 25% of Haduvio subjects evaluated at week 14 met the primary endpoint of a 4-point reduction in WI-NRS from baseline compared to 14% of placebo subjects.
  • Haduvio subjects experienced significantly greater improvements in ItchyQoL vs. placebo.
  • 55% of Haduvio subjects saw at least a 1-category improvement in the 5-point scale in their Prurigo Activity Scale (PAS) (pruriginous lesions with excoriations), vs. 38% on placebo.
  • The safety results of the trial were generally consistent with the known safety profile of Haduvio from previous trials. 
  • Earlier this year, the company reported encouraging interim data from the Phase 2 CANAL trial of Haduvio in idiopathic pulmonary fibrosis patients suffering from chronic cough.
  • Price Action: TRVI shares are up 36.6% at $2.76 during the premarket session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.